VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
DBD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
DBDDiebold Nixdorf, Incorporated
$63.04$2.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. DBD
  4. Financial Ratios

Diebold Nixdorf, Incorporated (DBD) Financial Ratios

Latest Ratios: P/E Ratio 24.8x · EV/EBITDA 6.3x · ROE 9.3%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

DBD Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$2.1B$2.5B$1.6B$1.9B———————
Enterprise Value$2.9B$3.3B$2.4B$2.7B———————
P/E Ratio →24.8226.73—1.35———————
P/S Ratio0.560.660.430.50———————
P/B Ratio2.122.291.721.73———————
P/FCF8.139.5912.28————————
P/OCF7.128.4010.85————————

P/E links to full P/E history page with 30-year chart

DBD EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—0.870.630.71———————
EV / EBITDA6.337.177.5412.52———————
EV / EBIT8.7515.9811.6917.97———————
EV / FCF—12.5817.98————————

DBD Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin26.4%26.4%24.5%23.3%21.9%26.7%26.5%24.4%19.5%22.3%22.5%
Operating Margin8.8%8.8%4.9%2.3%-6.1%3.5%0.6%5.3%-7.9%2.9%1.8%
Net Profit Margin2.5%2.5%-0.4%36.6%-16.8%-2.0%-6.9%-7.7%-12.4%-5.2%-5.4%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE9.3%9.3%-1.6%127.5%————-120.3%-23.6%-23.7%
ROA2.6%2.6%-0.4%38.1%-17.7%-2.2%-7.2%-8.4%-11.9%-4.6%-4.7%
ROIC14.0%14.0%7.6%4.4%-14.0%8.0%1.2%10.4%-13.1%4.5%3.1%
ROCE14.1%14.1%7.3%4.1%-13.2%7.3%1.1%9.5%-11.8%3.9%2.6%

DBD Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.061.061.121.26—————1.901.68
Debt / EBITDA2.542.543.336.36—8.5612.215.01—4.789.21
Net Debt / Equity—0.710.800.75—————1.351.07
Net Debt / EBITDA1.701.702.393.78—7.2010.624.40—3.385.87
Debt / FCF—2.995.70——28.63—21.85———
Interest Coverage2.422.421.300.60-1.200.74-0.01-0.16-2.09-0.67-1.40

DBD Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.301.301.321.521.101.081.131.181.401.381.44
Quick Ratio0.920.920.901.100.740.770.820.891.020.981.03
Cash Ratio0.300.300.250.400.210.240.220.180.250.350.39
Asset Turnover—0.991.060.901.131.111.071.161.060.880.63
Inventory Turnover5.385.385.364.894.605.265.767.146.045.013.48
Days Sales Outstanding—58.4557.2670.0664.5755.6360.5151.2858.7765.56101.38

DBD Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield4.0%3.7%—73.9%———————
FCF Yield12.3%10.4%8.1%————————
Buyback Yield6.1%5.2%0.0%0.0%———————
Total Shareholder Yield6.1%5.2%0.0%0.0%———————
Shares Outstanding—$37M$38M$64M$79M$78M$78M$77M$76M$76M$69M

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Revenue growth remains sluggish

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Discounted Earnings, Rich Multiple

DBD trades at 28.8x trailing earnings but only 13.6x forward, implying the market expects a sharp earnings rebound. According to reported figures, EV/EBITDA of 7.1x is below the peer NCR Atleos at 7.8x, suggesting relative undervaluation on an EBITDA basis.

The wide gap between trailing and forward P/E suggests the market is pricing in a significant earnings recovery, likely driven by the Q4 2025 spike. However, with revenue growth tepid and margins below peers, the forward multiple may be optimistic. The EV/EBITDA discount to NCR Atleos could indicate the market is skeptical of earnings sustainability, or it may reflect DBD's higher leverage and weaker cash flow consistency.

Margin Recovery Remains Uneven

Gross margin improved to 25.7% in Q2 2026 from 23.3% in Q1 2024, but operating margin remains volatile, swinging from 2.7% to 11.6% over the past ten quarters. As reported in financial statements, net margin has been negative in several quarters, indicating limited pricing power.

The Q4 2025 operating margin of 11.6% appears to be an outlier, as other quarters cluster in the 4-8% range. This suggests that the company's core operations generate modest profitability, and the recent improvement may be partly due to one-time items. Investors should monitor whether the gross margin can sustain above 26% and whether operating leverage can be achieved without revenue acceleration.

Returns on Capital Remain Subdued

ROIC has averaged around 2.5% over the last ten quarters, with a peak of 5.0% in Q4 2025, while ROE has been negative in several quarters. Based on reported figures, returns are far below the cost of capital, indicating value destruction.

The low and volatile ROIC suggests that DBD is not generating sufficient returns on its invested capital, which includes a significant amount of goodwill and intangibles. The Q4 2025 spike in ROIC to 5.0% was driven by an unusual earnings quarter, not a sustainable improvement in capital efficiency. Without a meaningful increase in margins or asset turnover, returns are unlikely to reach double digits.

Working Capital Swings Distort Efficiency

Cash conversion cycle has ranged from 63 to 86 days over the past ten quarters, with DSO improving to 57 days in Q2 2026 from 70 days in Q1 2024. According to recent filings, DPO has remained stable around 60-70 days, indicating limited supplier leverage.

The improvement in DSO suggests better receivables collection, but the CCC remains elevated due to high inventory days (76 days in Q2 2026). The volatility in working capital is a primary driver of cash flow swings, as seen in the large OCF fluctuations. This indicates that efficiency gains are not yet structural, and the company may be managing working capital to smooth earnings rather than improving underlying operations.

Leverage Eases but Debt Service Remains Tight

D/E improved to 0.97 in Q2 2026 from 1.12 in Q4 2024, but D/EBITDA remains high at 16.4x, and interest coverage is only 2.4x. As reported in financial statements, debt levels are still substantial relative to equity.

The decline in D/E is positive, but the D/EBITDA ratio is alarming, indicating that EBITDA is insufficient to cover debt obligations comfortably. Interest coverage of 2.4x is thin, leaving little room for earnings shocks. The Q4 2025 EBITDA spike temporarily improved leverage metrics, but subsequent quarters show a reversion, suggesting that the company's debt burden remains a key risk.

Liquidity Buffer Thins but Remains Adequate

Current ratio has declined to 1.27 in Q2 2026 from 1.45 in Q4 2024, while quick ratio is 0.83, indicating reliance on inventory. Based on reported figures, cash reserves have fallen to $282.4M, reducing the cushion.

The current ratio above 1.0 suggests short-term obligations are covered, but the quick ratio below 1.0 implies that inventory is a significant component of current assets. In a stress scenario, inventory may not be easily liquidated, and the company's ability to meet obligations could be strained. The declining cash position and volatile operating cash flow warrant close monitoring.

Trailing NCR Atleos on Key Metrics

DBD's ROE of 1.5% in Q2 2026 is far below NCR Atleos's 49.2%, and its net margin of 1.7% lags the peer's 3.7%. According to peer data, DBD's EV/EBITDA is lower, but this may reflect higher risk.

The comparison with NCR Atleos highlights DBD's weaker profitability and return generation. While DBD's lower EV/EBITDA could suggest undervaluation, it may also be a function of its higher leverage and less consistent cash flows. The gap in ROE is structural, driven by DBD's lower margins and asset efficiency, and is unlikely to close without a significant operational turnaround.

EV/EBITDA Misleads on Leverage

EV/EBITDA is often used to compare companies, but for DBD, it obscures the high debt load and volatile EBITDA. As reported in financial statements, D/EBITDA of 16.4x in Q2 2026 indicates that EBITDA is not a reliable measure of cash flow.

The EV/EBITDA multiple of 7.1x appears attractive, but it fails to capture the company's substantial debt and the variability of EBITDA. A more appropriate metric would be EV/EBIT or EV/FCF, which better reflect the company's ability to service debt. Investors should adjust for the one-time Q4 2025 earnings spike and focus on normalized EBITDA to assess true leverage.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open DBD Terminal

DBD Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

DBD — Frequently Asked Questions

Quick answers to the most common questions about buying DBD stock.

What is Diebold Nixdorf, Incorporated's P/E ratio?

Diebold Nixdorf, Incorporated's current P/E ratio is 24.8x. The historical average is 14.0x. This places it at the 50th percentile of its historical range.

What is Diebold Nixdorf, Incorporated's EV/EBITDA?

Diebold Nixdorf, Incorporated's current EV/EBITDA is 6.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.1x.

What is Diebold Nixdorf, Incorporated's ROE?

Diebold Nixdorf, Incorporated's return on equity (ROE) is 9.3%. The historical average is 6.2%.

Is DBD stock overvalued?

Based on historical data, Diebold Nixdorf, Incorporated is trading at a P/E of 24.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Diebold Nixdorf, Incorporated's profit margins?

Diebold Nixdorf, Incorporated has 26.4% gross margin and 8.8% operating margin.

How much debt does Diebold Nixdorf, Incorporated have?

Diebold Nixdorf, Incorporated's Debt/EBITDA ratio is 2.5x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.